Cytovale Inc. has posted a feverish run of wins lately. The company gained U.S. FDA clearance for its Intellisep rapid test for sepsis in January 2023, raised $84 million in a series C in November and just published results showing the test has negative predictive value of 97.5%.
Inflammatix Inc. received U.S. FDA breakthrough device designation for its Triverity acute infection and sepsis test system, which produces three readouts that could help emergency physicians quickly determine the proper course of treatment.
The time to diagnosis of sepsis infection to a patient in the hospital can be critical, with underdiagnosis resulting in rapid deterioration, risk of organ damage and need for readmission, and overdiagnosis leading to the avoidable and sometimes serious health consequences of overtreating patients with broad-spectrum antibiotics.
This randomized clinical trial compares the efficacy of sighs in addition to usual care vs usual care alone in improving clinical outcomes trauma patients recei
Between 2023 and 2033, the market for sepsis diagnostics is anticipated to grow at a CAGR of 8.1%. The market is anticipated to be worth US$ 561.2 million in 2023. By 2033, the valuation is anticipated to surpass US$ 1.2 billion.The sector is booming due to increased demand for antibiotic-resistant bacterial strains.